Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial
暂无分享,去创建一个
V. Torri | S. Marino | R. Pallini | E. Beghi | L. Tassi | E. Mazzon | M. Lampugnani | E. Dejana | R. Salman | A. Maggioni | R. Latini | R. Al‐Shahi Salman | C. Fusco | E. Mazzon | A. Petracca | M. Castori | E. Scola | S. Lanfranconi | R. Treglia | G. Faragò | F. Pignotti | L. D'agruma | E. Scelzo | R. Ciurleo | D. Novelli | M. Mangiavacchi | M. Malinverno | S. Marino | M. Tettamanti | C. Ungaro | M. Carriero | F. Lazzaroni | B. Zarino | P. d’Orio | E. Nicolis | U. de Grazia | G. Bertani | M. L. Fernandez | M. Poloni | G. Balconi | D. Ronchi | A. Prelle | J. Meessen | A. Vasamì | G. Valcamonica | S. Pogliani | A. Foresta | V. Torri | G. d’Alessandris | R. G. F. C. A. S. E. G. A. B. G. D. M. R. E. G. S. U. Pallini d’Alessandris Pignotti Sturiale Albane | C. Sturiale | A. Albanese | C. Bossi | C. Fusco | P. Raggi | A. Simeone | M. Buratti | M. Carrara | C. Regna-Gladin | F. Raucci | L. Tassi | Piergiorgio d’Orio | P. d’Orio | R. Pallini | Barbara Zarino | Giorgio d’Alessandris | Giuseppe Faragò | Leonardo d’Agruma | Enrico Bjorn Nicolis | Antonella Vasamì | G. d’Alessandris | B. Zarino | G. Faragò | L. D’Agruma | E. B. Nicolis | A. Vasamì | A. Vasami | E. Dejana | M. Castori | S. Lanfranconi | E. Scola | G. A. Bertani | R. Pallini | E. Mazzon | S. Marino | M. R. Carriero | E. Scelzo | G. Faragò | C. Fusco | L. Tassi | E. B. Nicolis | V. Torri | R. Latini | E. Scola | G. A. Bertani | R. Pallini | E. Mazzon | S. Marino | M. R. Carriero | E. Scelzo | G. Faragò | C. Fusco | V. Torri | M. L. Fernández
[1] C. Lengner,et al. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation , 2019, Science Translational Medicine.
[2] L. Morrison,et al. Familial Cerebral Cavernous Malformations , 2019, Stroke.
[3] L. Morrison,et al. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. , 2018, Neurosurgery.
[4] C. Sudlow,et al. Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis , 2018, British medical journal.
[5] Dean Y. Li,et al. Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations , 2018, Translational Stroke Research.
[6] Huan Tan,et al. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. , 2017, Journal of neurosurgery.
[7] C. Jack,et al. Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults: Mayo Clinic Study of Aging , 2017, JAMA neurology.
[8] B. Miller,et al. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. , 2017, The New England journal of medicine.
[9] Dean Y. Li,et al. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations , 2017, Nature.
[10] D. Kondziolka,et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel , 2017, Neurosurgery.
[11] R. Du,et al. Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis. , 2017, Journal of neurosurgery.
[12] Rachel B. Keller,et al. Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma. , 2016, JCI insight.
[13] L. Morrison,et al. Cerebral Cavernous Malformation, Familial , 2016 .
[14] R. Spetzler,et al. Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. , 2016, World neurosurgery.
[15] A. Algra,et al. Prognosis of cerebral cavernomas: on to treatment decisions , 2016, The Lancet Neurology.
[16] Robert D. Brown,et al. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data , 2016, The Lancet Neurology.
[17] Bruno Amati,et al. Degradation dynamics of microRNAs revealed by a novel pulse-chase approach , 2016, Genome research.
[18] S. Prey,et al. Safety of Propranolol Therapy for Severe Infantile Hemangioma. , 2016, JAMA.
[19] R. Shenkar,et al. Vascular Permeability in Cerebral Cavernous Malformations , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] C. Berul,et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. , 2015, The New England journal of medicine.
[21] Y. E. Chen,et al. Non-coding RNAs in cerebral endothelial pathophysiology: Emerging roles in stroke , 2014, Neurochemistry International.
[22] F. Jiang,et al. Circulating microRNAs Serve as Novel Biological Markers for Intracranial Aneurysms , 2014, Journal of the American Heart Association.
[23] C. Warlow,et al. Outcome after surgical or conservative management of cerebral cavernous malformations , 2014, Neurology.
[24] Jon Thacker,et al. Evaluation of Iron Content in Human Cerebral Cavernous Malformation Using Quantitative Susceptibility Mapping , 2014, Investigative radiology.
[25] A. Dupuy,et al. Successful treatment of multifocal intracerebral and spinal hemangiomas with propranolol. , 2014, Journal of the American Academy of Dermatology.
[26] D. Zanon,et al. Propranolol for Cerebral Cavernous Angiomatosis , 2014, Clinical pediatrics.
[27] L. Ferrarini,et al. EndMT contributes to the onset and progression of cerebral cavernous malformations , 2013, Nature.
[28] D. Torgerson,et al. Sample size calculations for pilot randomized trials: a confidence interval approach. , 2013, Journal of clinical epidemiology.
[29] K. Holland,et al. Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference , 2013, Pediatrics.
[30] L. S. Schultze Kool,et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. , 2011, Journal of the American Academy of Dermatology.
[31] H. Kraemer,et al. The role and interpretation of pilot studies in clinical research. , 2011, Journal of psychiatric research.
[32] G. Zipfel,et al. Update on the natural history of cavernous malformations and factors predicting aggressive clinical presentation. , 2010, Neurosurgical focus.
[33] M. Moschovi,et al. Propranolol Treatment for a Giant Infantile Brain Cavernoma , 2010, Journal of child neurology.
[34] W. Min,et al. Stabilization of VEGFR2 Signaling by Cerebral Cavernous Malformation 3 Is Critical for Vascular Development , 2010, Science Signaling.
[35] Yoshito Tsushima,et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis , 2009, BMJ : British Medical Journal.
[36] G. Steinberg,et al. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. , 2009, Human molecular genetics.
[37] Elisabetta Dejana,et al. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. , 2009, Developmental cell.
[38] U. Felbor,et al. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells , 2008, Human molecular genetics.
[39] L. Morrison,et al. Hemorrhage From Cavernous Malformations of the Brain: Definition and Reporting Standards , 2008, Stroke.
[40] E. Tournier-Lasserve,et al. Genetics of cavernous angiomas , 2007, The Lancet Neurology.
[41] J. Gault,et al. Biallelic Somatic and Germ Line CCM1 Truncating Mutations in a Cerebral Cavernous Malformation Lesion , 2005, Stroke.
[42] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[43] Fiona Peachey,et al. Data management and statistical analysis , 2000 .
[44] L. Brunereau,et al. Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families , 1998, The Lancet.
[45] R F Spetzler,et al. The natural history of familial cavernous malformations: results of an ongoing study. , 1994, Journal of neurosurgery.
[46] A M Rhodes,et al. Treatment decisions. , 1991, MCN. The American journal of maternal child nursing.
[47] Williams Ia. Letter: Levamisole and agranulocytosis. , 1976 .
[48] J. Black,et al. Preliminary CommunicationsA NEW ADRENERGIC: BETA-RECEPTOR ANTAGONIST , 1964 .
[49] J. Black,et al. A NEW ADRENERGIC , 1964 .
[50] J. Black,et al. A NEW ADRENERGIC BETARECEPTOR ANTAGONIST. , 1964, Lancet.